JP2022501350A5 - - Google Patents
Info
- Publication number
- JP2022501350A5 JP2022501350A5 JP2021515104A JP2021515104A JP2022501350A5 JP 2022501350 A5 JP2022501350 A5 JP 2022501350A5 JP 2021515104 A JP2021515104 A JP 2021515104A JP 2021515104 A JP2021515104 A JP 2021515104A JP 2022501350 A5 JP2022501350 A5 JP 2022501350A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- isomer
- acceptable salt
- compound according
- optionally substituted
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811094969.4 | 2018-09-19 | ||
| CN201811094969 | 2018-09-19 | ||
| PCT/CN2019/106687 WO2020057604A1 (zh) | 2018-09-19 | 2019-09-19 | Tlr8激动剂 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501350A JP2022501350A (ja) | 2022-01-06 |
| JP2022501350A5 true JP2022501350A5 (https=) | 2022-09-21 |
| JPWO2020057604A5 JPWO2020057604A5 (https=) | 2022-09-21 |
| JP7498702B2 JP7498702B2 (ja) | 2024-06-12 |
Family
ID=69888288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515104A Active JP7498702B2 (ja) | 2018-09-19 | 2019-09-19 | Ｔｌｒ８アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12054482B2 (https=) |
| EP (1) | EP3854794B1 (https=) |
| JP (1) | JP7498702B2 (https=) |
| KR (1) | KR102856089B1 (https=) |
| CN (2) | CN112805283B (https=) |
| AU (1) | AU2019344868B2 (https=) |
| CA (1) | CA3112953A1 (https=) |
| ES (1) | ES2999323T3 (https=) |
| PH (1) | PH12021550601A1 (https=) |
| SG (1) | SG11202102641RA (https=) |
| WO (1) | WO2020057604A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202102641RA (en) | 2018-09-19 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
| EP4122931B1 (en) * | 2020-03-18 | 2025-07-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline form of tlr8 agonist |
| CN116472047B (zh) * | 2021-11-05 | 2025-06-17 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| SG194852A1 (en) | 2011-05-18 | 2013-12-30 | Janssen R & D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| CN109923106B (zh) | 2016-09-02 | 2022-09-13 | 吉利德科学公司 | toll样受体调节剂化合物 |
| SG11202102641RA (en) | 2018-09-19 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
-
2019
- 2019-09-19 SG SG11202102641RA patent/SG11202102641RA/en unknown
- 2019-09-19 ES ES19862693T patent/ES2999323T3/es active Active
- 2019-09-19 AU AU2019344868A patent/AU2019344868B2/en active Active
- 2019-09-19 CN CN201980052513.8A patent/CN112805283B/zh active Active
- 2019-09-19 KR KR1020217011377A patent/KR102856089B1/ko active Active
- 2019-09-19 US US17/276,920 patent/US12054482B2/en active Active
- 2019-09-19 EP EP19862693.9A patent/EP3854794B1/en active Active
- 2019-09-19 JP JP2021515104A patent/JP7498702B2/ja active Active
- 2019-09-19 WO PCT/CN2019/106687 patent/WO2020057604A1/zh not_active Ceased
- 2019-09-19 CN CN202211301510.3A patent/CN115650979A/zh active Pending
- 2019-09-19 CA CA3112953A patent/CA3112953A1/en active Pending
-
2021
- 2021-03-17 PH PH12021550601A patent/PH12021550601A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012092103A5 (https=) | ||
| JP2022501350A5 (https=) | ||
| JP2021513534A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2018533593A5 (https=) | ||
| CN113784970A (zh) | Erk抑制剂及其应用 | |
| JP2016513130A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2019527234A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2019510082A5 (https=) | ||
| JP2019527233A5 (https=) | ||
| JP2013545785A5 (https=) | ||
| JP2014500861A5 (https=) | ||
| JP2005523922A5 (https=) | ||
| JP2014511892A5 (https=) | ||
| JP2012506389A5 (https=) | ||
| JP2015511958A5 (https=) | ||
| JP2013032389A5 (https=) | ||
| JP2016510323A5 (https=) | ||
| JP2017523169A5 (https=) | ||
| JP2015517555A5 (https=) | ||
| JP2009527462A5 (https=) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий |